Abstract | BACKGROUND & AIMS: METHODS:
LAM-R CHB patients were randomised 1:1 to receive TDF 300mg or FTC 200mg and TDF 300mg once daily in a prospective, double blind, study. The proportion of patients with plasma hepatitis B virus (HBV) DNA<69IU/ml (<400copies/ml) at week 96 (primary efficacy endpoint) was reported previously. Here we present week 240 follow-up data. RESULTS: Overall, 280 patients were randomised to receive TDF (n=141) or FTC/TDF (n=139), and 85.4% completed 240weeks of treatment. At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96). Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively). Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively). Overall, six patients achieved hepatitis B surface antigen ( HBsAg) loss and one patient ( FTC/TDF arm) had HBsAg seroconversion by week 240. No TDF resistance was observed up to week 240. Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%). The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively. CONCLUSIONS: TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240weeks. LAY SUMMARY: The goal of oral antiviral treatment for chronic hepatitis B (CHB) is to achieve and maintain undetectable HBV DNA levels. Treatment options with enhanced potency, and low risk of resistance development for patients infected with lamivudine resistant ( LAM-R) HBV are required. Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks. Clinical trial number: NCT00737568.
|
Authors | Scott Fung, Peter Kwan, Milotka Fabri, Andrzej Horban, Mijomir Pelemis, Hie-Won Hann, Selim Gurel, Florin A Caruntu, John F Flaherty, Benedetta Massetto, Kyungpil Kim, Kathryn M Kitrinos, G Mani Subramanian, John G McHutchison, Leland J Yee, Magdy Elkhashab, Thomas Berg, Ioan Sporea, Cihan Yurdaydin, Petr Husa, Maciej S Jablkowski, Edward Gane |
Journal | Journal of hepatology
(J Hepatol)
Vol. 66
Issue 1
Pg. 11-18
(01 2017)
ISSN: 1600-0641 [Electronic] Netherlands |
PMID | 27545497
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Antiviral Agents
- DNA, Viral
- Hepatitis B Surface Antigens
- Hepatitis B e Antigens
- Tenofovir
- Emtricitabine
|
Topics |
- Adult
- Antiviral Agents
(administration & dosage, adverse effects)
- DNA, Viral
(blood)
- Double-Blind Method
- Drug Monitoring
- Drug Resistance, Viral
- Drug Therapy, Combination
(methods)
- Emtricitabine
(administration & dosage, adverse effects)
- Female
- Hepatitis B Surface Antigens
(blood)
- Hepatitis B e Antigens
(blood)
- Hepatitis B virus
(drug effects, isolation & purification, physiology)
- Hepatitis B, Chronic
(drug therapy, virology)
- Humans
- Male
- Middle Aged
- Tenofovir
(administration & dosage, adverse effects)
- Treatment Outcome
- Viral Load
(drug effects)
|